Randomized double-blind trial of intracoronary urokinase for acute myocardial infarction. Multicenter study.

Kambara, Hirofumi; Kammatsuse, Katsuo; Nobuyoshi, M.; Sato, Hajime; Sasayama, Shígetake; Nagao, Keisuke; Nakashima, Mitsuyoshi; Kawai, Chuichi

doi:10.1253/jcj.51.1072

Cited by 9 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12 The patency rate was 74% for the urokinase group and 17% for the placebo group. However, urokinase possesses little specific affinity for fibrin and, therefore, will activate both circulating and fibrin-bound plasminogen, possibly resulting in serious bleeding complications.…”

mentioning

confidence: 92%

Randomized, double-blinded multicenter study. Comparison of intracoronary single-chain urokinase-type plasminogen activator, pro-urokinase (GE-0943), and intracoronary urokinase in patients with acute myocardial infarction.

et al. 1988

View full text Add to dashboard Cite

Coronary recanalization rates and changes in the coagulation and fibrinolysis system were evaluated in a randomized fashion in patients with acute myocardial infarction after intracoronary administration of single-chain urokinase-type plasminogen activator (pro-urokinase: GE-0943) or urokinase. Three groups of patients were studied: group H (n=50), 6,000 units pro-urokinase i.c.; group L (n=44), 3,000 units pro-urokinase i.c.; and group U (n=54), 960,000 IU urokinase i.c. Coronary recanalization rates determined angiographically after 45 minutes of intracoronary infusion averaged 90% in group H, 59% in group L, and 61% in group U. The differences were statistically significant between group H and the latter two groups. Pro-urokinase affected plasma proteins of the fibrinolytic system to a lesser degree than urokinase. Bleeding complications were present in one patient in group L, in none in group H, and in five in group U. Thus, intracoronary administration of 6,000 units pro-urokinase is more effective in coronary thrombolysis and causes less systemic fibrinogenolysis than intracoronary administration of urokinase. (Circulation 1988;78:899-905) Rapid and effective dissolution of intracoronary thrombi by systemic or selective infusion of thrombolytic agents has been demonstrated convincingly in many clinical studies.

show abstract

mentioning

confidence: 92%

Randomized, double-blinded multicenter study. Comparison of intracoronary single-chain urokinase-type plasminogen activator, pro-urokinase (GE-0943), and intracoronary urokinase in patients with acute myocardial infarction.

et al. 1988

View full text Add to dashboard Cite

show abstract

“…Since the formation of thrombus on the coronary artery wall is reported to produce AIHD due to the blockade of coronary circulation, thrombolytic agents are used as therapeutic agents for the recanalization of the occluded artery for the resumption of normal circulation [15][16][17][18].…”

Section: Introductionmentioning

confidence: 99%

The thrombolytic effect of aspirin in animal model

Karmohapatra

Kahn

Sinha

2007

J Thromb Thrombolysis

View full text Add to dashboard Cite

show abstract

Febrile Reaction Associated With Urokinase

Shibley

Clifton

1994

Pharmacotherapy

View full text Add to dashboard Cite

Urokinase is an endogenously produced human proteolytic enzyme used to treat many thrombotic disorders. A 54-year-old man with recurrent myocardial infarction experienced fever during intracoronary urokinase infusion into a saphenous vein graft; the fever resolved after discontinuation of the infusion. After excluding all other possible etiologies of fever, urokinase was determined to be the cause. Several studies indicated that this reaction may be associated with urokinase infusion, but it is actually recognized by few individuals. This is the first published case report of the adverse event to our knowledge.

show abstract

Randomized double-blind trial of intracoronary urokinase for acute myocardial infarction. Multicenter study.

Cited by 9 publications

References 18 publications

Randomized, double-blinded multicenter study. Comparison of intracoronary single-chain urokinase-type plasminogen activator, pro-urokinase (GE-0943), and intracoronary urokinase in patients with acute myocardial infarction.

Randomized, double-blinded multicenter study. Comparison of intracoronary single-chain urokinase-type plasminogen activator, pro-urokinase (GE-0943), and intracoronary urokinase in patients with acute myocardial infarction.

The thrombolytic effect of aspirin in animal model

Febrile Reaction Associated With Urokinase

Contact Info

Product

Resources

About